Want to see DRTS full AI Analyst Report?
DRTS Stock Chart & Stats
$12.50
-$0.12(-0.96%)
At close: 4:00 PM EDT
$12.50
-$0.12(-0.96%)
Day’s Range― - ―
52-Week Range$3.00 - $14.75
Previous CloseN/A
Volume333.05K
Average Volume (3M)751.50K
Market Cap
$1.29B
Enterprise Value$1.05K
Total Cash (Recent Filing)$100.64M
Total Debt (Recent Filing)$15.15M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 24, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding90,325,874
10 Day Avg. Volume654,776
30 Day Avg. Volume751,504
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-12.18
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.67Price Target Upside9.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.88
Revenue Forecast (FY)$1.23M
Bulls Say, Bears Say
Bulls Say
Regulatory Momentum (FDA)FDA clearance to finish REGAIN enrollment based on strong interim safety/efficacy materially derisks the U.S. clinical pathway. This approval enables completion of pivotal data collection, supports future regulatory filings, and signals constructive agency interaction that aids long-term approval odds.
Compelling Clinical SignalsConsistent 100% local disease control across multiple small trials and indications (glioblastoma, pancreatic, skin) strengthens the therapy’s scientific case. Durable, cross‑indication efficacy and favorable safety improve the chance of successful registration and adoption in specialized oncology centers over the medium term.
Strategic Commercialization Partner & CapitalA long-term commercialization and supply agreement with Tolmar plus $20M equity provides strategic U.S. market access, upfront funding for manufacturing scale-up and significant milestone upside. This reduces execution risk, accelerates commercial readiness, and anchors a pathway to revenue for prostate indication.
Bears Say
No Revenue To DateThe company reports no product revenue through 2025 while operating losses have widened materially. Absent successful regulatory approval and commercial launch, persistent zero revenue means the business remains pre-revenue, increasing financing needs and making long-term sustainability contingent on trial and market success.
Sustained Cash BurnChronic negative operating and free cash flow drive reliance on external funding to sustain trials, regulatory activity, and manufacturing build-out. Continued cash burn elevates liquidity and execution risk over the next 2–6 months if additional non-dilutive or equity financing is unavailable or delayed.
Dilution And Negative ROE RiskAlthough equity recovered from prior deficits and leverage is moderate, persistent negative returns on equity and ongoing losses mean management may need further equity raises or partnerships. That outcome risks shareholder dilution and reduces long-term return prospects unless clinical progress quickly translates to revenues.
Alpha Tau Medical Ltd News
DRTS FAQ
What was Alpha Tau Medical Ltd’s price range in the past 12 months?
Alpha Tau Medical Ltd lowest stock price was $3.00 and its highest was $14.75 in the past 12 months.
What is Alpha Tau Medical Ltd’s market cap?
Alpha Tau Medical Ltd’s market cap is $1.29B.
When is Alpha Tau Medical Ltd’s upcoming earnings report date?
Alpha Tau Medical Ltd’s upcoming earnings report date is Nov 24, 2026 which is in 98 days.
How were Alpha Tau Medical Ltd’s earnings last quarter?
Alpha Tau Medical Ltd released its earnings results on Aug 10, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.141 by -$0.359.
Is Alpha Tau Medical Ltd overvalued?
According to Wall Street analysts Alpha Tau Medical Ltd’s price is currently Undervalued.
Does Alpha Tau Medical Ltd pay dividends?
Alpha Tau Medical Ltd does not currently pay dividends.
What is Alpha Tau Medical Ltd’s EPS estimate?
Alpha Tau Medical Ltd’s EPS estimate is -0.14.
How many shares outstanding does Alpha Tau Medical Ltd have?
Alpha Tau Medical Ltd has 90,325,874 shares outstanding.
What happened to Alpha Tau Medical Ltd’s price movement after its last earnings report?
Alpha Tau Medical Ltd reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.141. Following the earnings report the stock price went up 4.926%.
Which hedge fund is a major shareholder of Alpha Tau Medical Ltd?
Currently, no hedge funds are holding shares in DRTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Tau Medical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.67 (9.33% Upside)
$13.67 (9.33% Upside)
Blogger Sentiment
Bullish
DRTS Sentiment 87%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
313.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.00%
Trailing 12-Months
Company Description
Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
DRTS Stock 12 Month Forecast
Average Price Target
$13.67
▲(9.33% Upside)
Technical Analysis
Larimar Therapeutics
―
Capricor Therapeutics
―
Benitec Biopharma
―
Aura Biosciences Inc
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.10% Insiders
0.08% Mutual Funds
4.93% Other Institutional Investors
94.64% Public Companies and
Individual Investors